Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort ascending
Mar
2
2023
The Health AI Frontier: New Opportunities for Innovation Across the Health Care Sector Foley & Lardner LLP
Sep
22
2015
En Banc Federal Circuit Preserves The Patent Laches Defense Over Dissent Foley & Lardner LLP
Oct
22
2019
USPTO October 2019 Patent Eligibility Guidance Update Includes New Guidance And Examples For Life Sciences Foley & Lardner LLP
Mar
24
2016
Sequenom Throws Diagnostic Method Patents At Mercy Of Supreme Court Foley & Lardner LLP
May
9
2016
New USPTO Guidance On Patent Eligibility Of Diagnostic Methods Foley & Lardner LLP
Jul
11
2016
New USPTO P3 Program Offers Applicant Participation In After Final Conference Foley & Lardner LLP
Jul
14
2016
Janssen Seeks Injunction Against Remicade Biosimilar Based On Cell Culture Patent Foley & Lardner LLP
Nov
13
2023
A Look at FDA’s Proposed Changes to Labeling for Biosimilars and Interchangeable Biosimilars Foley & Lardner LLP
Nov
14
2023
EPA Seeks Comment on Its Sweeping Proposal to Ban Manufacture and Commercial and Industrial Use of Trichloroethylene (TCE) Foley & Lardner LLP
Nov
29
2023
Who Regulates My Product? Foley & Lardner LLP
Dec
5
2023
Proposed Amendments to the Proposition 65 Regulatory Landscape – Changes to Clear and Reasonable Warnings and Safe Harbor Methods under Article 6 Foley & Lardner LLP
Oct
5
2016
Judge Grants Gilead Motion To Invalidate Remicade Patent For Obviousness-Type Double Patenting Foley & Lardner LLP
Jul
23
2020
COVID-19: FDA Clears Path for Test to Screen Asymptomatic Individuals Foley & Lardner LLP
Mar
14
2024
My Healthy Food Product is Ready to Go to Market – What About its Packaging? Foley & Lardner LLP
Feb
13
2017
Food and Drug Administration Hits “Pause” on Regulation of Laboratory Developed Tests Foley & Lardner LLP
Apr
1
2024
FDA: New Guidance for Non-interventional Studies of Drug Safety and Effectiveness Foley & Lardner LLP
May
2
2017
How Will The Supreme Court Choreograph The Biosimilar Patent Dance? Foley & Lardner LLP
Jan
20
2021
The Indefinite Peril Of Claim Drafting Foley & Lardner LLP
Aug
7
2017
New Jersey’s Telemedicine Law: What Providers Need to Know Foley & Lardner LLP
Jun
15
2021
50 State Map of MAC Laws – Can PBMs No Longer Rely on ERISA Preemption to Avoid Certain State Laws? Foley & Lardner LLP
Apr
4
2018
Medicaid Drug Rebate Agreements: Changes Require Immediate Action By Pharmaceutical Manufacturers Foley & Lardner LLP
Sep
26
2018
Refusing to Hire Medical Marijuana User Puts Employer in Jeopardy Foley & Lardner LLP
Oct
2
2018
Blocking Patent Discounts Objective Indicia Of Non-Obviousness Foley & Lardner LLP
Jun
6
2022
June 2022 Food and Beverage Review: Government Enforcement Defense & Investigations Foley & Lardner LLP
Oct
12
2022
Takeaways from President Biden’s Announcement on Marijuana Policy Reform Foley & Lardner LLP
Nov
18
2022
Supply Chain Shortages in the Meat and Poultry Industries Foley & Lardner LLP
Jun
4
2015
Federal Circuit Hears Oral Arguments in Neupogen Biosimilar Case Foley & Lardner LLP
Dec
12
2022
American Hospital Association Urges DEA to Issue Special Registration for Telemedicine Controlled Substances Foley & Lardner LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins